Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
South Korean drugmaker Daewoong Pharmaceutical Co. inked a US$430 million deal to provide US pharmaceutical venture firm Neurogastrx Inc. with its technology for fexuprazan, the novel drug candidate for gastroesophageal reflux.
The technology deal with Neurogastrx made the US the fourth country that the South Korean firm has signed technology deals with, after China, Brazil, and Mexico.
The said countries account for almost 40 percent of the global gastrointestinal disorder market.
The combined value of the deals is already over 1 trillion won.
Daewoong Pharmaceutical will also receive 13.5 percent of Neurogastrx's shares.
Daewoong Pharmaceutical claims that fexuprazan, a class of potassium-competitive acid blockers, exhibited a cure rate of 99 percent during the phase three clinical trials and is expected to win approval from local drug authorities soon.
Neurogastrx is a privately-held biopharmaceutical company that develops therapies for gastrointestinal disorders.
